Future research should pay more attention to the regulatory mechanisms of Trx1 activity and its expression and functional differences in patients with PAH, which will help slow down the development of disulfide stress in PAH and thus help to develop effective treatment strategies. This evidence concerns the gene TXN and pulmonary arterial hypertension.